ID   7SuR
AC   CVCL_XI63
DR   cancercelllines; CVCL_XI63
DR   CCRID; 4201PAT-CCTCC00547
DR   Wikidata; Q93310157
RX   Patent=CN104988122B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014217.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:38940; Sunitinib.
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1051 ! 786-O
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 10
//
RX   Patent=CN104988122B;
RA   Qu L., Wang L.-H., Liu B., Chen C., Wu Z.-J., Zhang W.;
RT   "Renal cancer sunitinib drug-resistant cell system and establishment
RT   method thereof.";
RL   Patent number CN104988122B, 21-Sep-2018.
//